MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ
2.500
0.000
0.00%
After Hours: 2.500 0 0.00% 17:29 02/23 EST
OPEN
2.520
PREV CLOSE
2.500
HIGH
2.529
LOW
2.460
VOLUME
86.08K
TURNOVER
0
52 WEEK HIGH
6.60
52 WEEK LOW
2.340
MARKET CAP
60.15M
P/E (TTM)
2.118
1D
5D
1M
3M
1Y
5Y
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Ocuphire Pharma, Inc. Is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders. George Magrath will be presenting a company overview at the BIO CEO & Investor Conference in 2024 in New York City.
Barchart · 2d ago
Weekly Report: what happened at OCUP last week (0212-0216)?
Weekly Report · 6d ago
Ocuphire Pharma Welcomes Nirav Jhaveri as New CFO
TipRanks · 02/16 21:12
Ocuphire Pharma appointed Nirav Jhaveri as CFO
Healthcare Ocuphire Pharma appointed Nirav Jhaveri as CFO. The company also announced appointment of Ash Jayagopal, as Chief Scientific and Development Officer.  OCUP stock is up 2.7% in the last day of trading.
Seeking Alpha · 02/14 13:37
Ocuphire Pharma Strengthens Leadership Team with Key Appointments; Nirav Jhaveri, C.F.A, M.B.A. Appointed As Chief Financial Officer
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer and Nirav Jhaveri, C.F.A., appointed as Chief Financial Officer. Ocuphire is a clinical-stage ophthalmic biopharmaceutical company. The company is focused on developing therapies for the treatment of retinal and refractive eye disorders.
Benzinga · 02/14 13:17
Weekly Report: what happened at OCUP last week (0205-0209)?
Weekly Report · 02/12 10:01
Ocuphire Pharma Announces Presentation On APX3330 At The Annual Angiogenesis, Exudation, And Degeneration 2024 Conference
Ocuphire Pharma, Inc. Presented clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy. The company is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies. The results were presented at the 21st Annual Angiogenesis Conference.
Benzinga · 02/05 13:05
Weekly Report: what happened at OCUP last week (0129-0202)?
Weekly Report · 02/05 10:06
More
About OCUP
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its pipeline includes two small molecule product candidates targeting several of such indications. Nyxol Eye Drops (Nyxol) is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically induced mydriasis (RM), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (DLD) (halos, glares and starbursts). Its product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases. The Company has also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.

Webull offers Ocuphire Pharma Inc stock information, including NASDAQ: OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.